160 related articles for article (PubMed ID: 35726394)
1. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.
DiPeri TP; Newhook TE; Prakash LR; Ikoma N; Maxwell JE; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2022 Nov; 126(6):1021-1027. PubMed ID: 35726394
[TBL] [Abstract][Full Text] [Related]
2. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
Newhook TE; Vreeland TJ; Griffin JF; Tidwell RSS; Prakash LR; Koay EJ; Ludmir EB; Smaglo BG; Pant S; Overman M; Wolff RA; Ikoma N; Maxwell J; Kim MP; Lee JE; Katz MHG; Tzeng CD
Ann Surg; 2023 Mar; 277(3):484-490. PubMed ID: 36649067
[TBL] [Abstract][Full Text] [Related]
3. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
4. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
5. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
7. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
9. Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?
Anger F; Lock JF; Klein I; Hartlapp I; Wiegering A; Germer CT; Kunzmann V; Löb S
Ann Surg Oncol; 2022 Dec; 29(13):8523-8533. PubMed ID: 36094690
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.
Thalji SZ; Aldakkak M; Christians KK; Clarke CN; George B; Kamgar M; Erickson BA; Hall WA; Chisholm P; Kulkarni N; Doucette S; Evans DB; Tsai S
J Surg Oncol; 2023 Jul; 128(1):41-50. PubMed ID: 36960919
[TBL] [Abstract][Full Text] [Related]
11. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
[TBL] [Abstract][Full Text] [Related]
12. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
[TBL] [Abstract][Full Text] [Related]
13. Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study.
Li XL; Liu ZP; Su XX; Gong Y; Yang YS; Zhao XL; Li ZM; Ding JJ; Zhu Y; Yin DL; Yu C; Zhou JX; Zhang D; Ding R; Chen W; Cheng Y; Yue P; Wang ZR; Zhang YQ; Jiang Y; Yin XY; Bai J; Dai HS; Lau WY; Chen ZY;
Int J Surg; 2024 Apr; ():. PubMed ID: 38626431
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
Chen T; Zhang MG; Xu HX; Wang WQ; Liu L; Yu XJ
Medicine (Baltimore); 2015 May; 94(19):e751. PubMed ID: 25984661
[TBL] [Abstract][Full Text] [Related]
15. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
Nurmi AM; Mustonen H; Haglund C; Seppänen H
Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
[TBL] [Abstract][Full Text] [Related]
18. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Zheng Z; Wang X; Huang Y; Lu X; Chi P
Colorectal Dis; 2020 Dec; 22(12):2068-2077. PubMed ID: 32936987
[TBL] [Abstract][Full Text] [Related]
20. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
Amburn T; Davenport D; Patel R; Moss J; Pandalai P; Kim J; Cavnar M
Am Surg; 2023 Nov; 89(11):4469-4478. PubMed ID: 35921431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]